Halozyme Therapeutics, Inc. (LON:0J2O)
52.87
-0.22 (-0.41%)
At close: Jun 20, 2025
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
2.40M GBP
Profits / Employee
1.07M GBP
Market Cap
4.83B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Indivior | 1,051 |
Halozyme Therapeutics News
- 6 days ago - Halozyme Therapeutics: The Waters Become Muddled - Seeking Alpha
- 8 days ago - Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
- 16 days ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
- 23 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 23 days ago - What's Driving the Market Sentiment Around Halozyme Therapeutics? - Benzinga
- 23 days ago - Price Over Earnings Overview: Halozyme Therapeutics - Benzinga
- 23 days ago - Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - PRNewsWire
- 4 weeks ago - Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga